Chart-Typ:
Zeitraum:
| Johnson & Johnson: New Data Reinforces Efficacy, Sustained Disease Control Of IMAAVY | NEW BRUNSWICK (dpa-AFX) - Johnson & Johnson (JNJ) announced new data from the Phase 3 Vivacity-MG3 study and ongoing open label extension in a broad population of antibody-positive adults with... ► Artikel lesen |
| Johnson & Johnson: IMAAVY (nipocalimab-aahu) shows over two years of sustained disease control in a broad population with generalized myasthenia gravis (gMG) | Through 120 weeks of follow-up, IMAAVY delivered sustained clinical improvements and reductions in total IgG in antibody-positive adult patients including anti-AChR+... ► Artikel lesen |
| Johnson & Johnson Announces CE Mark Approval for the New ETHICON 4000 Stapler | Designed to elevate the surgical experience and deliver reliable staple line integrity across a broad range of tissue thickness1 the ETHICON 4000 Surgical Stapler is certified for use in open and... ► Artikel lesen |
| Biogen To Acquire TJ Bio's Rights To Felzartamab In The Greater China Region | WESTON (dpa-AFX) - Biogen Inc. (BIIB) and TJ Biopharma have entered into a definitive agreement under which Biogen has agreed to acquire TJ Bio's exclusive rights to felzartamab in the Greater... ► Artikel lesen |
| Biogen Inc.: Biogen Enters into Agreement with TJ Biopharma for Felzartamab Assets in the Greater China Region | With this transaction, Biogen now owns exclusive worldwide development and commercialization rights to felzartamab, consolidating global rights under one ownerAdvancing felzartamab - a CD38-directed... ► Artikel lesen |
| Weekly Buzz: ARS Pharmaceuticals Gains FDA Nod; Novo Nordisk received FDA approval for Awiqli; EU Expands Kerendia Label; Eli Lilly Acquires Centessa Pharmaceuticals; Biogen Snaps Up Apellis Pharmaceuticals | BASEL (dpa-AFX) - This week's biotech landscape witnessed regulatory approvals across the U.S., EU, and China, acquisitions, a few key trial goal misses and positive clinical trial data readouts... ► Artikel lesen |
| EU Approves DAWNZERA For Hereditary Angioedema, Says Ionis And Otsuka | TOKYO (dpa-AFX) - Ionis Pharmaceuticals, Inc. (IONS) and Otsuka Pharmaceutical Co., Ltd. on Wednesday said the European Commission has approved Dawnzera to prevent repeated attacks of hereditary... ► Artikel lesen |
| Ionis Pharmaceuticals, Inc.: DAWNZERA (donidalorsen) approved in the European Union for hereditary angioedema (HAE) | Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) and Otsuka Pharmaceutical Co., Ltd. (Otsuka) today announced that the European Commission (EC) has approved DAWNZERA (donidalorsen) in the European Union... ► Artikel lesen |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu BG MEDICINE INC finden Sie auf Wallstreet Online.